 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- PRO1107 / ProfoundBio
A novel PTK7-directed antibody-drug conjugate (ADC) PRO1107 demonstrated broad antitumor activity with a promising safety profile in preclinical models (Exhibit Hall B) - Sep 27, 2023 - Abstract #SITC2023SITC_357;
It may also carry an expanded therapeutic index compared to other antitubulin-based ADCs on conventional linker-drug platforms. PRO1107 is a highly exciting novel agent to bring forward to the clinic for the treatment of various solid tumors.